Vemurafenib (ZELBORAF, Hoffmann-La Roche Inc; Figure 1) is a first-in-class selective inhibitor of the BRAF serine-threonine kinase, FDA approved for the treatment of metastatic melanoma harboring ...

a melanoma researcher at the University of Pittsburgh. “We finally have a randomized controlled trial that is positive.” Finalized phase 1 results of a BRAF inhibitor, developed by the ...

Sometimes the melanoma cannot be removed ... They are called cancer growth blockers or inhibitors. You usually have a BRAF protein inhibitor with a MEK protein inhibitor as they work better together.

BRAF, a member of a serine/threonine ... currently utilized for the therapy of malignant metastatic melanoma. They include RAF inhibitors, such as sorafenib and vemurafenib, or MEK inhibitors ...

This helped pharmaceutical companies develop selective inhibitors of mutated BRAF – including vemurafenib and dabrafenib, which have been approved to treat melanoma. These treatments are frequently ...

Patients with melanoma and colorectal cancer ... currently investigating the possibility of BRAF degraders since BRAF/MEK inhibitor combinations are being utilized to treat a variety of cancer ...

Amtagvi is indicated for intravenous infusion to treat advanced unresectable or metastatic melanoma in ... and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.

This BRAF/CRAF inhibitor is being evaluated in a Phase 3 study called SEACRAFT-2 as part of a combination therapy with Mikinist (trametinib) from Novartis to treat NRASm melanoma. The primary ...

"These data from the BREAKWATER study show the potential for this targeted treatment regimen to become the new standard of care for people with BRAF V600E-mutant metastatic colorectal cancer ...

Doctors treat melanoma that can be removed with surgery (resectable ... These are called cancer growth blockers or inhibitors. You usually have a BRAF protein inhibitor with a MEK protein inhibitor.

Patients with melanoma and colorectal cancer ... Companies are currently investigating the possibility of BRAF degraders since BRAF/MEK inhibitor combinations are being utilized to treat a variety of ...